Dianthus Therapeutics, Inc. (NASDAQ:DNTH – Get Free Report) shares reached a new 52-week high on Thursday . Weiss Ratings restated a “sell (d-)” rating on shares of Dianthus Therapeutics in a research note on Wednesday, January 21st. Dianthus Therapeutics Company Profile(Get Free Report)Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York. Further ReadingReceive News & Ratings for Dianthus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dianthus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.